reveng: venetoclax and obinutuzumab in cll
Published 2 years ago • 803 plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
3:15
overview of a phase ib study of venetoclax and obinutuzumab in cll
-
3:22
combining venetoclax and obinutuzumab in the treatment of cll
-
2:11
atezolizumab with venetoclax and obinutuzumab in patients with cll
-
0:48
venetoclax and obinutuzumab for cll
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
-
1:35
cll: venetoclax in combination with obinutuzumab
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
4:52
apoptosis and venetoclax
-
3:33
venetoclax (bcl 2 inhibitor)
-
3:46
long-term follow-up of venetoclax in cll
-
10:24
fixed-duration therapy with venetoclax-obinutuzumab in frontline cll
-
2:08
the role of venetoclax in the treatment of cll
-
0:59
5-year follow-up results of cll14: obinutuzumab venetoclax vs obinutuzumab chlorambucil in cll
-
1:59
acalabrutinib, venetoclax and obinutuzumab upfront for cll
-
0:58
the impact of the clinical trial of venetoclax (abt-199) and obinutuzumab in cll
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
1:43
six-year update from cll14: fixed-duration venetoclax obinutuzumab for previously untreated cll
-
0:45
obinutuzumab and venetoclax for high-risk cll: upcoming cll14 trial
-
2:50
venetoclax and ibrutinib based approaches in cll
-
1:58
entospletinib in combination with obinutuzumab in r/r cll
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll